You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
希瑪眼科(03309.HK)已出售Belkin Vision Ltd.的股權予愛爾康
格隆匯 05-16 21:22

格隆匯5月16日丨希瑪眼科(03309.HK)公吿,公司全資附屬公司香港(國際)眼科醫療集團有限公司已出售其於Belkin Vision Ltd.(出售公司)的股權予Alcon Pharmaceuticals Ltd(愛爾康),其於2023年12月31日的賬面值為23.3百萬港元,並分類為按公平值計入其他全面收入的金融資產。

代價如下:完成時的固定現金代價約6.4百萬美元;及或然代價不超過17.0百萬美元,此乃基於公司的最佳估計,視是否達到與年度銷售目標相關的里程碑而定。

出售事項完成前,香港眼科醫療持有出售公司約10.7%股權或按悉數攤薄基準計算的8.6%股權,而香港眼科醫療於2020年5月已投資於出售公司。根據公司的估計,公司預計於其他全面收入錄得從固定現金代價約6.4百萬美元產生的税前收益,金額估計約為26.0百萬港元。完成後,香港眼科醫療將不再持有出售公司的任何權益。

公司預期從出售事項收取的所得款項將用作營運資金及一般企業用途。

出售公司是一家根據以色列法律註冊的公司,主要從事Eagle激光設備的開發及商業化,其目的為提供一線青光眼護理。據董事所深知、全悉及確信,出售公司的產品於2022年5月獲得歐洲新指令下醫療器械製造商MDR的CE標誌,並於2023年12月獲得美國食品藥物管理局(FDA)的批准。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account